Skip to content

A Study to Assess the Impact of Associated ACE Gene Polymorphism in The Severity of Covid-19.

A Prospective, Quasi Randomize, Cross-sectional Study to Assess the Impact of Associated ACE Gene Polymorphism in The Severity of Covid-19.

Status
Unknown
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2021/08/035928
Enrollment
1000
Registered
2021-08-25
Start date
Unknown
Completion date
Unknown
Last updated
2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere Health Condition 2: B342- Coronavirus infection, unspecified

Interventions

Intervention1: Not applicable: Not applicable

Sponsors

Adichunchanagiri University
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients diagnosed with Covid-19 by any diagnostic tool (i.e., RT-PCR, CT scan or X-Ray and any other as per the clinical decision taken by the treating physician). Patients who have been admitted or in self-quarantined. All the patients who will give a consent.

Exclusion criteria

Exclusion criteria: Patient with Chronic Kidney disease, undergoing dialysis and whose creatinine clearance is Evidence of cirrhosis, Hepatitis B virus or Hepatitis C virus infection. Patients who are unable to give a consent.

Design outcomes

Primary

MeasureTime frame
The study will help to find out the relation between the ACE gene polymorphism and the severity of the Covid-19. This study can measure the ACE II, ID and II genotype frequencies in Indian population. Timepoint: 3 years

Secondary

MeasureTime frame
This study will assist in prioritizing high risk patients to take a decision in the choice of treatment.Timepoint: 2 year

Countries

India

Contacts

Public ContactRajesh Venkataraman

Adichunchanagiri Institute of Medical sciences

sanjay.mysore82@gmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026